AARD Stock Overview

A clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. More details

AARD fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Risk Analysis

Highly volatile share price over the past 3 months compared to the US market

Earnings are forecast to decline by an average of 43% per year for the next 3 years

Makes less than USD$1m in revenue ($0)

Currently unprofitable and not forecast to become profitable over the next 3 years

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Aardvark Therapeutics, Inc. Competitors

Third Harmonic Bio

NasdaqGM:THRD

US$232.9m

Atea Pharmaceuticals

NasdaqGS:AVIR

US$253.3m

BioStem Technologies

OTCPK:BSEM

US$253.8m

Terns Pharmaceuticals

NasdaqGS:TERN

US$263.8m

Price History & Performance

Summary of share price highs, lows and changes for Aardvark Therapeutics
Historical stock prices
Current Share Price	US$10.14
52 Week High	US$19.58
52 Week Low	US$4.88
Beta	0
1 Month Change	42.02%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-29.14%

Recent updates

Shareholder Returns

	AARD	US Pharmaceuticals	US Market
7D	-2.8%	-3.8%	3.9%
1Y	n/a	-7.4%	11.6%

Return vs Industry: Insufficient data to determine how AARD performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how AARD performed against the US Market.

Price Volatility

Is AARD's price volatile compared to industry and market?
AARD volatility
AARD Average Weekly Movement	18.7%
Pharmaceuticals Industry Average Movement	11.0%
Market Average Movement	8.1%
10% most volatile stocks in US Market	16.6%
10% least volatile stocks in US Market	4.2%

Stable Share Price: AARD's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine AARD's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2017	22	Tien-Li Lee	aardvarktherapeutics.com

Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen, which is in the Phase 3 clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in the Phase 2 clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from the treatment of craniopharyngioma, including surgery or radiation. The company is also developing ARD-201, which is in the Phase 1 clinical trial for the treatment of obesity.

Aardvark Therapeutics, Inc. Fundamentals Summary

How do Aardvark Therapeutics's earnings and revenue compare to its market cap?
AARD fundamental statistics
Market cap	US$238.00m
Earnings (TTM)	-US$20.59m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-10.7x

P/E Ratio

Is AARD overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AARD income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$20.59m
Earnings	-US$20.59m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.95
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did AARD perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/13 00:41
End of Day Share Price	2025/05/13 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Aardvark Therapeutics, Inc. is covered by 4 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Timothy Anderson	BofA Global Research
Joshua Schimmer	Cantor Fitzgerald & Co.
Michael Ulz	Morgan Stanley

Aardvark Therapeutics NasdaqGS:AARD Stock Report